-DOCSTART- -X- O
Vaccines -X- _ O
have -X- _ O
had -X- _ O
a -X- _ O
profound -X- _ O
impact -X- _ O
on -X- _ O
the -X- _ O
management -X- _ O
and -X- _ O
prevention -X- _ O
of -X- _ O
infectious -X- _ O
disease. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
vaccines -X- _ O
against -X- _ O
chronic -X- _ O
diseases -X- _ O
has -X- _ O
attracted -X- _ O
considerable -X- _ O
interest -X- _ O
as -X- _ O
an -X- _ O
approach -X- _ O
to -X- _ O
prevent -X- _ O
, -X- _ O
rather -X- _ O
than -X- _ O
treat -X- _ O
, -X- _ O
conditions -X- _ O
such -X- _ O
as -X- _ O
cancer -X- _ O
, -X- _ O
Alzheimer’s -X- _ O
disease -X- _ O
, -X- _ O
and -X- _ O
others. -X- _ O
Subunit -X- _ O
vaccines -X- _ O
consist -X- _ O
of -X- _ O
nongenetic -X- _ O
components -X- _ O
of -X- _ O
the -X- _ O
infectious -X- _ O
agent -X- _ O
or -X- _ O
disease-related -X- _ O
epitope. -X- _ O
In -X- _ O
this -X- _ O
Review -X- _ O
, -X- _ O
we -X- _ O
discuss -X- _ O
peptide-based -X- _ B-Intervention
vaccines -X- _ I-Intervention
and -X- _ O
their -X- _ O
potential -X- _ O
in -X- _ O
three -X- _ O
therapeutic -X- _ O
areas -X- _ O
: -X- _ O
infectious -X- _ B-Patient
disease -X- _ I-Patient
, -X- _ I-Patient
Alzheimer’s -X- _ I-Patient
disease -X- _ I-Patient
, -X- _ I-Patient
and -X- _ I-Patient
cancer. -X- _ I-Patient
We -X- _ O
discuss -X- _ O
factors -X- _ O
that -X- _ O
contribute -X- _ O
to -X- _ O
vaccine -X- _ O
efficacy -X- _ O
and -X- _ O
how -X- _ O
these -X- _ O
parameters -X- _ O
may -X- _ O
potentially -X- _ O
be -X- _ O
modulated -X- _ O
by -X- _ O
design. -X- _ O
We -X- _ O
examine -X- _ O
both -X- _ O
clinically -X- _ O
tested -X- _ O
vaccines -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
nascent -X- _ O
approaches -X- _ O
and -X- _ O
explore -X- _ O
current -X- _ O
challenges -X- _ O
and -X- _ O
potential -X- _ O
remedies. -X- _ O
While -X- _ O
peptide -X- _ B-Intervention
vaccines -X- _ I-Intervention
hold -X- _ O
substantial -X- _ O
promise -X- _ O
in -X- _ O
the -X- _ O
prevention -X- _ O
of -X- _ O
human -X- _ O
disease -X- _ O
, -X- _ O
many -X- _ O
obstacles -X- _ O
remain -X- _ O
that -X- _ O
have -X- _ O
hampered -X- _ O
their -X- _ O
clinical -X- _ O
use -X- _ O
; -X- _ O
thus -X- _ O
, -X- _ O
continued -X- _ O
research -X- _ O
efforts -X- _ O
to -X- _ O
address -X- _ O
these -X- _ O
challenges -X- _ O
are -X- _ O
warranted -X- _ O
. -X- _ O

